NASDAQ:TCDATricida Stock Price, Forecast & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA shares have decreased by 50.8% and is now trading at $13.80.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tricida.

Tricida Inc (NASDAQ:TCDA) announced its earnings results on Wednesday, August, 5th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.46) by $0.30.
View Tricida's earnings history.

2 analysts have issued twelve-month price objectives for Tricida's shares. Their forecasts range from $50.00 to $50.00. On average, they anticipate Tricida's share price to reach $50.00 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price.
View analysts' price targets for Tricida.

Media stories about TCDA stock have been trending somewhat negative on Thursday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tricida earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Tricida.

Tricida saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,740,000 shares, an increase of 5.3% from the June 15th total of 4,500,000 shares. Based on an average daily trading volume, of 334,200 shares, the days-to-cover ratio is presently 14.2 days. Approximately 12.3% of the shares of the company are sold short.
View Tricida's Current Options Chain.

Some companies that are related to Tricida include Insmed (INSM), Deciphera Pharmaceuticals (DCPH), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), SAGE Therapeutics (SAGE), Pacira Biosciences (PCRX), TG Therapeutics (TGTX), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Uniqure (QURE), Aurinia Pharmaceuticals (AUPH) and Xencor (XNCR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), CytomX Therapeutics (CTMX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida's stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.38%), Swiss National Bank (0.13%), UBS Group AG (0.12%), SG Americas Securities LLC (0.11%), MAI Capital Management (0.08%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida.

TCDA stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Russell Investments Group Ltd., Swiss National Bank, ProShare Advisors LLC, UBS Group AG, MAI Capital Management, Principal Financial Group Inc., and Candriam Luxembourg S.C.A.. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $13.80.

Tricida has a market capitalization of $689.34 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]